2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the provided data.

**1) Return Rate Comparison:**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company providing personalized health and wellness solutions directly to consumers.
*   **HIMS Cumulative Return:** 121.51%
*   **VOO (S&P 500) Cumulative Return:** 77.16%
*   **Divergence:**
    *   Current: 54.7
    *   Relative Divergence: 34.5

**Analysis:** HIMS has significantly outperformed the S&P 500, VOO, over the period for which the cumulative returns are measured. The current divergence is 54.7, placing it at the 34.5th percentile of its historical divergence range, suggesting it's not currently at an extreme high or low relative to its past performance compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha  | Beta   | Cap(B) |
|------------|---------|-------|--------|--------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0% | 0.0    | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0% | -0.0   | 1.5    |
| 2021-2023  | -65.0%  | 78.6% | -67.0% | -0.1   | 2.0    |
| 2022-2024  | 119.0%  | 79.4% | 98.0%  | -0.0   | 5.5    |
| 2023-2025  | 126.0%  | 80.8% | 58.0%  | 0.1    | 7.8    |

**Analysis:**

*   **CAGR:** The company has seen both significant declines and impressive growth in different periods. Recent years (2022-2025) show strong positive returns.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant volatility and risk.
*   **Alpha:** The Alpha values fluctuate, suggesting periods of underperformance and outperformance relative to the market. The recent Alpha of 58.0% for 2023-2025 is positive, implying outperformance.
*   **Beta:** The Beta values are relatively low (around 0), which indicates that the stock's returns are not closely correlated with the overall market.
*   **Cap(B):** The company's market capitalization has been increasing, showing growth in the company's size.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 34.31
*   **Previous Close:** 34.67
*   **Change:** -1.04%
*   **5-day SMA:** 34.878
*   **20-day SMA:** 36.8975
*   **60-day SMA:** 43.0687

**Analysis:** The stock price has recently decreased, closing lower than the previous day. The 5-day SMA is below the 20-day SMA, and both are below the 60-day SMA, suggesting a potential short-term downward trend.

**3) Technical Indicators and Expected Return:**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 23.10 (Oversold)
*   **PPO:** -0.1228
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -2.7 (Short-term decline)
*   **Expected Return:** 31.3% (Long-term, >2 years, excess return over S&P 500)

**Analysis:**

*   The MRI suggests a high investment recommendation, but should be considered in the context of the other indicators.
*   The RSI is very low, indicating the stock is oversold and potentially due for a rebound.
*   The PPO is negative but close to zero.
*   The hybrid signal suggests a "buy" recommendation, allocating 100% of cash to purchase shares.
*   The recent negative change in relative divergence indicates a short-term downward trend.
*   The expected return is quite high, suggesting confidence in the company's long-term prospects.

**4) Recent News & Significant Events:**

*   **Stock Fell 4% This Week:** Indicates recent negative price action.
*   **Carnegie Investment Counsel Acquires Shares:** A positive sign, suggesting institutional investor confidence.
*   **HIMS vs. TDOC Comparison:** Highlights the competitive landscape within the telehealth industry.
*   **Share Repurchase Program:** A positive sign, potentially indicating management believes the stock is undervalued.
*   **Market Panic is Irrational:** An opinion piece suggesting the market may be overreacting to recent events.
*   **Moves to Bolster Weight-Loss Biz:**  Indicates strategic initiatives to expand the company's offerings.

**Analysis:** Recent news is mixed. While the share repurchase program and institutional investment are positive, the recent stock price decline and comparison with competitors raise concerns. The focus on weight-loss initiatives is a significant strategic move.

**4-2) Analyst Opinions:**

*   **Mean Rating:** No data provided
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00

**Analysis:** The average analyst target price suggests potential upside from the current price. However, the wide range between the high and low targets reflects uncertainty among analysts. Recent rating changes are not available, limiting insight into recent analyst sentiment shifts.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-11-03 | 0.07  | 0.60 B$    |
| 2025-08-04 | 0.19  | 0.54 B$    |
| 2025-05-05 | 0.22  | 0.59 B$    |
| 2024-11-04 | 0.35  | 0.40 B$    |
| 2025-11-03 | 0.35  | 0.40 B$    |

**Analysis:**
* It's important to note the table includes a repeated entry for 2025-11-03. Assuming one is a typo, the data shows a trend of fluctuating EPS and increasing revenue. The EPS seems to have decreased from 0.35 in late 2024/early 2025 to more recent values around 0.07 to 0.22. Revenue has shown growth.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.60B  | 73.80%        |
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity | ROE    |
|--------------|--------|--------|
| 2025-09-30   | $0.58B | 2.72%  |
| 2025-06-30   | $0.56B | 7.55%  |
| 2025-03-31   | $0.55B | 9.01%  |
| 2024-12-31   | $0.48B | 5.46%  |
| 2024-09-30   | $0.44B | 17.18% |

**Analysis:**

*   **Revenue:** Revenue has generally been increasing quarter over quarter, demonstrating growth.
*   **Profit Margin:** Profit margins are high, consistently above 73%, but have shown a slight decrease in the most recent quarter.
*   **Equity:** Equity has been steadily increasing, reflecting a strengthening balance sheet.
*   **ROE:** ROE has fluctuated but decreased significantly in the most recent quarter, which may be a point of concern.

**7) Comprehensive Analysis (Summary):**

Hims & Hers Health Inc. (HIMS) presents a mixed picture.

*   **Positives:**
    *   Historically strong outperformance relative to the S&P 500.
    *   High expected return (31.3% long-term).
    *   Strong revenue growth.
    *   High profit margins.
    *   Share repurchase program and recent institutional investment.
    *   Oversold RSI suggesting potential for a rebound.
*   **Negatives:**
    *   High volatility (high MDD).
    *   Recent negative price action.
    *   Decreasing ROE in the most recent quarter.
    *   Fluctuating EPS.
    *   Short-term downward trend based on moving averages and divergence change.
    *   Mixed analyst opinions (wide target price range).
    *   Increased competition within the telehealth industry.
    *   Recent reduction in profit margin
    *   Declining EPS

**Conclusion:**

HIMS is a growth company with significant potential but also carries considerable risk. The high expected return and strong revenue growth are attractive, but the volatility, recent price weakness, and fluctuating earnings should give investors pause. The company's strategic focus on weight-loss and increasing market capitalization suggest positive growth trajectories. The recent decrease in ROE and profit margins should be monitored closely. Overall, HIMS might be a suitable investment for those with a high-risk tolerance and a long-term investment horizon, particularly given the MRI recommendation, but careful due diligence is essential.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.